Pharmacology of exenatide (synthetic exendin-4) for the treatment of type 2 diabetes

Current Opinion in Investigational Drugs

Volumn 4, Issue 4, 2003, Pages 401-405

  Nielsen, Loretta L ^a   Baron, Alain D ^a  

^a AMYLIN PHARMACEUTICALS INC   (United States)

Author keywords

AC 2993; Diabetes; Exenatide; Glycemic control; Glycosylated hemoglobin (A1C); Synthetic exendin 4

Indexed keywords

ANTIDIABETIC AGENT; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; HEMOGLOBIN A1C; INSULIN; INSULIN DERIVATIVE; METFORMIN; ORAL ANTIDIABETIC AGENT; PLACEBO; SULFONYLUREA DERIVATIVE; UNCLASSIFIED DRUG;

BLOOD GLUCOSE MONITORING; CARDIOVASCULAR DISEASE; CELL FUNCTION; CLINICAL TRIAL; DIET RESTRICTION; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG HALF LIFE; DRUG MECHANISM; DRUG STRUCTURE; DRUG TOLERABILITY; GLUCOSE BLOOD LEVEL; HEADACHE; HOMEOSTASIS; HUMAN; HYPERCORTISOLISM; HYPOGLYCEMIA; LONG TERM CARE; MAINTENANCE THERAPY; NAUSEA; NAUSEA AND VOMITING; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OPTIMAL DRUG DOSE; PANCREAS ISLET BETA CELL; REVIEW; SIDE EFFECT; STRUCTURE ANALYSIS; WEIGHT GAIN;

ANIMALS; BLOOD GLUCOSE; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; DIABETES MELLITUS, TYPE 2; HEMOGLOBIN A, GLYCOSYLATED; HOMEOSTASIS; HUMANS; HYPOGLYCEMIC AGENTS; PEPTIDES; RECOMBINANT PROTEINS; VENOMS;

EID: 0038519125     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (56)

1. American Diabetes Association: Postprandial blood glucose. Diabetes Care (2001) 24(4):775-778.
2. Kahn SE, Porte D Jr: Pathophysiology of type II diabetes mellitus. In: Diabetes Mellitus, 5th Edition. Porte D Jr, Sherwin RS (Eds), Appleton and Lange, Stamford, CT, USA (1997):487-512.
3. Weyer C, Bogardus C, Mott DM, Pratley RE: The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest (1999) 104(6):787-794.
4. Harris MI, Eastman RC, Cowie CC, Flegal KM, Eberhardt MS: Racial and ethnic differences in glycemic control of adults with type 2 diabetes. Diabetes Care (1999) 22(3):403-408.
5. UK Prospective Diabetes Study Group. Overview of 6 years' therapy of type II diabetes: A progressive disease. Diabetes (1995) 44(11):1249-1258.
6. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet (1998) 352(9131): 837-853.
7. Mudaliar S, Edelman SV: Insulin therapy in type 2 diabetes. Endocrinol Metab Clin North Am (2001) 30(4):935-982.
8. Wright A, Burden ACF, Paisey RB, Cull CA, Holman RR: Sulfonylurea inadequacy: Efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the UK. Prospective Diabetes Study (UKPDS 57). Diabetes Care (2002) 25(2):330-336.
9. Inzucchi SE: Oral antihyperglycemic therapy for type 2 diabetes: Scientific review. J Am Med Assoc (2002) 287(3):360-372.
10. DeFronzo RA: Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med (1991) 131(4):281-303.
11. Eng J, Kleinman WA, Singh L, Singh G, Raufman JP: Isolation and characterization of exendin-4, an exendin-3 analogue from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J Biol Chem (1992) 267(11):7402-7405.
12. Young A, Blase E, Petrella E, Seward M: Exendin-4 is a circulating meal-related peptide in the gila monster (Heloderma suspectum). Diabetes (1999) 48(Suppl 1):Abs A425.
13. Chen YE, Drucker DJ: Tissue-specific expression of unique mRNAs that encode proglucagon-derived peptides or exendin 4 in the lizard. J Biol Chem (1997) 272(7):4108-4115.
14. Kieffer TJ, McIntosh CH, Pederson RA: Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology (1995) 136(8):3585-3596.
15. Deacon CF, Nauck MA, Toft-Nielsen M, Pridal L, Willms B, Holst JJ: Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes (1995) 44(9):1126-1131.
16. Nauck MA, Sauerwald A, Ritzel R, Holst JJ, Schmiegel W: Influence of glucagon-like peptide 1 on fasting glycemia in type 2 diabetic patients treated with insulin after sulfonylurea secondary failure. Diabetes Care (1998) 21(11):1925-1931.
17. Zander M, Madsbad S, Madsen JL, Holst JJ: Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes: A parallel-group study. Lancet (2002) 359(9309):824-830.
18. Egan JM, Clocquet AR, Elahi D: The insulinotropic effect of acute exendin-4 administered to humans: Comparison of nondiabetic state to type 2 diabetes. J Clin Endocrinol Metab (2002) 87(3):1282-1290.
19. Parkes DG, Pittner R, Jodka C, Smith P, Young A: Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro. Metabolism (2001) 50(5):583-589.
20. Kolterman OG, Buse JB, Fineman MS, Gaines E, Heintz S, Bicsak TA, Taylor K, Kim D, Aisporna M, Wang Y, Baron AD: Synthetic exendin-4 (AC2993) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab (2003). in press. AC-2993 acutely and markedly reduced fasting and post-prandial glucose concentrations in patients with type 2 diabetes. During fasting, glucose-dependent enhancement of insulin secretion and suppression of glucagon secretion were the predominant mechanisms. Post-prandially, slowing of gastric emptying was also operative.
21. Young AA, Gedulin BR, Bhavsar S, Bodkin N, Jodka C, Hansen B, Denaro M: Glucose-lowering and insulin-sensitizing actions of exendin-4: Studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta). Diabetes (1999) 48(5):1026-1034. Exendin-4 dose-dependently improved glycemic control and stimulated glucose-dependent insulin secretion in three animal models of type 2 diabetes. Chronic administration of exendin-4 was associated with decreases in food intake, body weight, A1C levels and plasma lactate, while insulin sensitivity was increased.
22. Gedulin B, Jodka C, Hoyt J: Exendin-4 (AC-2993) decreases glucagon secretion during hyperglycemic clamps in diabetic fatty Zucker rats. Diabetes (1999) 48:Abs A199.
23. Jodka C, Gedulin B, Young A: Exendin-4 potently regulates gastric emptying in rats. Diabetes (1998) 47:Abs 403A.
24. Rayner CK, Samsom M, Jones KL, Horowitz M: Relationships of upper gastrointestinal motor and sensory function with glycemic control. Diabetes Care (2001) 24(2):371-381.
25. Phillips L, Fineman M, Taylor K, Baron A, Ludwig E, Grasela T: Population modeling to guide phase 3 dose selection for AC-2993 (synthetic exendin-4). Clin Pharmacol Ther (2002) 71:Abs P29.
26. Bhavsar S, Watkins J, Young A: Comparison of central and peripheral effects of exendin-4 and GLP-1 on food intake in rats. 80th Annual Meeting Endocrine Society, Bethesda, MD, USA (1998) Abs 433.
27. Szayna M, Doyle ME, Betkey JA, Holloway HW, Spencer RGS, Greig NH, Egan JM: Exendin-4 decelerates food intake, weight gain, and fat deposition in Zucker rats. Endocrinology (2000) 141(6):1936-1941. Obese adult Zucker rats were given exendin-4 daily for 2 weeks, then twice daily for 6 weeks. Exendin-4 reduced food intake and the rise in body weight observed in untreated diabetic rats, improved glycemic control, stimulated glucose-dependent insulin secretion and suppressed the increase in A1C levels observed in untreated rats.
28. Xu G, Stoffers DA, Habener JF, Bonner-Weir S: Exendin-4 stimulates both β-cell replication and neogenesis, resulting in increased β-cell mass and improved glucose tolerance in diabetic rats. Diabetes (1999) 48(12):2270-2276. Exendin-4 or vehicle were administered daily for 4 weeks to sham or 90 to 95% pancreatectomized, moderately hyperglycemic rats. Exendin-4 stimulated pancreatic β-cell neogenesis and proliferation.
29. Tourrel C, Bailbé D, Lacorne M, Meile MJ, Kergoat M, Portha B: Persistent improvement of type 2 diabetes in the Goto-Kakizaki rat model by expansion of the β-cell mass during the prediabetic period with glucagon-like peptide-1 or exendin-4. Diabetes (2002) 51(5):1443-1452. Goto-Kakizaki rats develop diabetes due to a deficiency in neonatal β-cell mass and have basal hyperglycemia within 3 weeks after birth. Exendin-4 or GLP-1 given daily during the first week after birth (days 2 to 6 postnatally) resulted in increased pancreatic insulin content and total β-cell mass by day 7 postnatally. This translated into a long-term benefit on diasease amelioration in adult rats.
30. Tourrel C, Bailbé D, Meile M-J, Kergoat M, Portha B: Glucagon-like peptide-1 and exendin-4 stimulate β-cell neogenesis in streptozotocin-treated newborn rats resulting in persistently improved glucose homeostasis at adult age. Diabetes (2001) 50(7):1562-1570. Diabetes was induced in neonatal rats by injection of streptozotocin at birth. Exendin-4 or GLP-1 given on days 2 to 6 postnatally promoted β-cell regeneration and long-term glycemic control.
31. Goke R, Fehmann HC, Linn T, Schmidt H, Krause M, Eng J, Goke B: Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting β-cells. J Biol Chem (1993) 268(26):19650-19655.
32. Greig NH, Holloway HW, De Ore KA, Jani D, Wang Y, Zhou J, Garant MJ, Egan JM: Once daily injection of exendin-4 to diabetic mice achieves long-term beneficial effects on blood glucose concentrations. Diabetologia (1999) 42(1):45-50.
33. Parkes D, Jodka C, Smith P, Nayak S, Rinehart L, Gingerich R, Chen K, Young A: Pharmacokinetic actions of exendin-4 in the rat: Comparison with glucagon-like peptide-1. Drug Dev Res (2001) 53(4):260-267.
34. Henquin J-C: Triggering and amplifying pathways of regulation of insulin secretion by glucose. Diabetes (2000) 49(11):1751-1760.
35. Gedulin B, Lawler R, Jodka C, Young A: Amylin inhibits pentagastrin-stimulated gastric acid secretion: Comparison glucagon-like peptide-1 and exendin-4. Diabetes (1997) 46:Abs 188A.
36. Nishizawa M, Nakabayashi H, Kawai K, Ito T, Kawakami S, Nakagawa A, Niijima A, Uchida K: The hepatic vagal reception of intraportal GLP-1 is via receptor different from the pancreatic GLP-1 receptor. J Auton Nerv Syst (2000) 80(1-2):14-21.
37. Vella A, Shah P, Reed AS, Adkins AS, Basu R, Rizza RA: Lack of effect of exendin-4 and glucagon-like peptide-1-(7,36)-amide on insulin action in non-diabetic humans. Diabetologia (2002) 45(10):1410-1415.
38. Idris I, Patiag D, Gray S, Donelly R: Exendin-4 increases insulin sensitivity via a PI-3-kinase-dependent mechanism: Contrasting effects of GLP-1. Biochem Pharmacol (2002) 63(5):993-996.
39. Burcelin R, Da Costa A, Drucker D, Thorens B: Glucose competence of the heptoportal vein sensor requires the presence of an activated glucagon-like peptide-1 receptor. Diabetes (2001) 50(8):1720-1728.
40. Kolterman O, Young G, Parker J, Amin D, Prickett K: Stimulation of endogenous insulin secretion by subcutaneous AC-2993 (synthetic exendin-4) in healthy overnight fasted volunteers. Diabetes (1999) 48(Suppl 1):Abs A199
41. Fineman MS, Bicsak TA, Shen LZ, Taylor K, Gaines E, Varns A, Kim D, Baron AD: Effect on glycemic control of synthetic exendin-4 (AC-2993) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes. Diabetes Care (2003): manuscript submitted. Treatment with AC-2993 for 28 days (twice a day at 0.08 μg/kg) significantly improved glycemic control as indicated by reductions in A1C, serum fructosamine and post-prandial plasma glucose. Improvement in β-cell function, as measured by HOMA, was observed. Nausea was the most common side effect.
42. Fineman M, Shen L, Smitzi J, Aisporna A, Bicsak T, Taylor K, Baron A: Unique study design: Evaluation of the effect of dose titration on dose-limiting nausea. Clin Pharmacol Ther (2002) 71:Abs P19.
43. Fineman M, Young A, Gaines E, Prickett K: Dose-response for postprandial glucose-lowering effect of synthetic exendin-4 (AC-2993) in subjects with type 2 diabetes. Diabetes (2000) 49(Suppl 1):Abs A106.
44. Phillips L, Fineman M, Taylor K, Baron A, Ludwig E, Grasela T: Population modeling to guide phase 3 dose selection for AC-2993 (synthetic exendin-4). Clin Pharmacol Ther (2002) 71:Abs MPI-96.
45. Taylor K, Kim D, Bicsak T, Heintz S, Varns A, Aisporna M, Fineman MS, Baron A: Continuous subcutaneous infusion of AC-2993 (synthetic exendin-4) provides sustained day-long glycemic control to patients with type 2 diabetes. Diabetes (2002) 51(Suppl 2):Abs A85.
46. Reaven GM, Chen YD, Golay A, Swislocki AL, Jaspan JB: Documentation of hyperglucagonemia throughout the day in nonobese and obese patients with non insulin-dependent diabetes mellitus. J Clin Endocrinol Metab (1987) 64(1):106-110.
47. Baron AD, Schaeffer L, Shragg P, Kolterman OG: Role of hyperglucagonemia in maintenance of increased rates of hepatic glucose output in type II diabetics. Diabetes (1987) 36(3):274-283.
48. Mahler RJ, Adler ML: Type 2 diabetes mellitus: Update on diagnosis, pathophysiology, and treatment. J Clin Endocrinol Metab (1999) 84(4):1165-1171.
49. Moore MC, Cherrington AD: Regulation of net hepatic glucose uptake: Interaction of neural and pancreatic mechanisms. Reprod Nutr Dev (1996) 36(4):399-406.
50. Green GM, Guan D, Schwartz JG, Phillips WT. Accelerated gastric emptying of glucose in Zucker type 2 diabetic rats: Role in postprandial hyperglycaemia. Diabetologia (1997) 40(2):136-142.
51. Harju E, Nordback I: Postprandial hyperglycemia after different carbohydrates in patients with total gastrectomy. Surg Gynecol Obstet (1987) 165(1):41-45.
52. Moyses C, Young A, Kolterman O: Modulation of gastric emptying as a therapeutic approach to glycaemic control. Diabetic Med (1996) 12(9 Suppl 5):34-38.
53. Edwards CM, Stanley SA, Davis R, Brynes AE, Frost GS, Seal LJ, Ghatei MA, Bloom SR: Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers. Am J Physiol Endocrinol Metab (2001) 281(1):E155-E161.
54. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: Insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia (1985) 28(7):412-419.
55. Ryan AS, Egan JM, Habener JF, Elahi D: Insulinotropic hormone glucagon-like peptide-1-(7-37) appears not to augment insulin-mediated glucose uptake in young men during euglycemia. J Clin Endocrinol Metab (1998) 83(7):2399-2404.
56. Egan JM, Meneilly GS, Elahi D: Effects of one month bolus subcutaneous administration of exendin-4 in type 2 diabetes. Am J Physiol Endocrinol Metab (2002): epublished ahead of print.